Sanofi Is Built to Ignore a Political Headline - Buy on a Clear Setup
Sanofi's fundamentals and pipeline momentum make it resilient to headline risk from vaccine-policy debate. Recent results show broad-based growth and an upgraded 2026 outlook; the trade idea is a mid-term long with an entry at $45.40, a stop at $43.00 and a target at $52.00 (45 trading days).